CRVS stock icon

Corvus Pharmaceuticals
CRVS

$2.02
1.46%
 

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's main product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Employees: 28

0
Funds holding %
of 6,665 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1% less call options, than puts

Call options by funds: $53.2K | Put options by funds: $53.8K

2.63% less ownership

Funds ownership: 39.12% [Q4 2023] → 36.49% (-2.63%) [Q1 2024]

5% less capital invested

Capital invested by funds: $33.7M [Q4 2023] → $31.8M (-$1.83M) [Q1 2024]

6% less funds holding

Funds holding: 48 [Q4 2023] → 45 (-3) [Q1 2024]

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

33% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 9

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3.5
73%
upside
Avg. target
$6.17
205%
upside
High target
$8
296%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Oppenheimer
Jeff Jones
296%upside
$8
Outperform
Maintained
7 May 2024
Mizuho
Graig Suvannavejh
73%upside
$3.5
Neutral
Maintained
27 Mar 2024
Oppenheimer
Jeff Jones
247%upside
$7
Outperform
Maintained
20 Mar 2024

Financial journalist opinion

Based on 4 articles about CRVS published over the past 30 days